 Continuous infusion weekly cisplatin pancreatic carcinoma Mid-Atlantic Oncology Program study Fifty-six patients biopsy-proven metastatic measurable adenocarcinoma pancreas combination protracted intravenous infusion low dose weekly bolus cisplatin weeks rest period objective response rate patients complete response confidence intervals median survival time treated patients months patients alive year median survival time proportion alive year prior reports large patient groups due patient selection